Dannielle Appelhans

Direktor/Vorstandsmitglied bei GENERATION BIO CO.

Vermögen: 60 200 $ am 30.04.2024

41 Jahre

Health Technology

Consumer Services

Finance

Aktive Positionen von Dannielle Appelhans

Unternehmen	Position	Beginn	Ende
GENERATION BIO CO.	Direktor/Vorstandsmitglied	15.07.2022	-
Cour Pharmaceuticals Development Co., Inc. Cour Pharmaceuticals Development Co., Inc. BiotechnologyHealth Technology Cour Pharmaceuticals Development Co., Inc. engages in the development of therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. Its product pipeline include celiac disease, peanut allergy, multiple sclerosis, and neutralizing antibodies. The company was founded by John J. Puisis and Jim Herrmann and is headquartered in Chicago, IL.	Geschäftsführer	19.07.2023	-

Unternehmen	Position	Beginn	Ende
RUBIUS THERAPEUTICS	Vorstandsvorsitzender	15.11.2022	03.03.2023
	Geschäftsführer	09.08.2021	15.11.2022
	Präsident	15.11.2022	03.03.2023
AVEXIS INC	Technik-/Wissenschafts-/F&E-Leiter	01.01.2020	01.01.2021

MIT Sloan School of Management	Masters Business Admin
University of Michigan	Undergraduate Degree
Massachusetts Institute of Technology	Graduate Degree

International

Vereinigte Staaten

Operativ

Sektoral

Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Börsennotierte Unternehmen	1
GENERATION BIO CO.	Health Technology

Private Unternehmen	3
Rubius Therapeutics, Inc. Rubius Therapeutics, Inc. BiotechnologyHealth Technology Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA.	Health Technology
Novartis Gene Therapies, Inc. Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL.	Health Technology
Cour Pharmaceuticals Development Co., Inc. Cour Pharmaceuticals Development Co., Inc. BiotechnologyHealth Technology Cour Pharmaceuticals Development Co., Inc. engages in the development of therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. Its product pipeline include celiac disease, peanut allergy, multiple sclerosis, and neutralizing antibodies. The company was founded by John J. Puisis and Jim Herrmann and is headquartered in Chicago, IL.	Health Technology